Basel Switzerland, Kuopio Finland – February 6th 2018.
Aurealis Pharma, a private biopharmaceutical company developing novel three-in-one combination biologics for chronic inflammation and cancer, announced today that CEO Juha Yrjänheikki will attend and present the company´s progress at the Swiss Nordic Bio 2018 partnering and investor event in Zurich on February 8th 2018.
The presentation is scheduled for:
- Time: Thursday, February 8th 2018 at 10:55 am.
- Location: Renaissance Zurich Tower Hotel, Room: Bavaria B.
“We are looking forward to this intensive one day partnering and investor event. We will present and speak with investors and pharma about our chronic wound product AUP-16, which is in clinical trial application filing stage. We will also update the audience on our pre-clinical programs on cancer and osteoarthritis” said CEO Juha Yrjänheikki.
About SWISS NORDIC BIO
Swiss Nordic Bio in Zurich is a high-level partnering and investor event where Swiss and Nordic biotech startups, pharmaceutical companies and investors meet. Swiss Nordic Bio carries 12 years of tradition, previously Swiss Scandinavian Bio-Business Seminar, and is organized by the Nordic countries in cooperation with Swiss partners.